Glenmark's FabiFlu approved for coronavirus treatment in India, costs Rs 103 per tablet

Mumbai-based Glenmark Pharmaceuticals have launched a new antiviral drug - Favipiravir with brand name FabiFlu - for the treatment of mild to moderate Covid-19 patients. The firm has become the first Indian company to commercially launch the antiviral drug.

https://www.indiatoday.in/india/story/coronavirus-treatment-drug-glenmark-fabiflu-favipiravir-launch-india-rs-103-per-tablet-reduce-viral-load-1691066-2020-06-20

Coronavirus replication

https://www.ncbi.nlm.nih.gov/books/NBK554776/figure/article-52171.image.f1/

RdRp is the main enzyme of transcription-replication complex

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2322833/

Favipiravir mechanism of action and its study

https://www.biorxiv.org/content/10.1101/2020.05.15.098731v1.full.pdf+html

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study

https://www.sciencedirect.com/science/article/pii/S2095809920300631?via%3Dihub

Potential coronavirus drug approved for marketing

Favipiravir, an antiviral that has shown potential in treating the novel coronavirus, was approved for marketing, the Taizhou government of Zhejiang province announced Sunday.

https://www.chinadaily.com.cn/a/202002/17/WS5e49efc2a310128217277fa3.html

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

Therapeutic options in response to the 2019-nCoV outbreak are urgently needed. Here, we discuss the potential for repurposing existing antiviral agents to treat 2019-nCoV infection (now known as COVID-19), some of which are already moving into clinical trials.

https://www.nature.com/articles/d41573-020-00016-0

Fujifilm Announces the Start of a Phase III Clinical Trial of Influenza Antiviral Drug Avigan (favipiravir) on COVID-19 in Japan and Commits to Increasing Production

https://www.drugs.com/clinical_trials/fujifilm-announces-start-phase-iii-clinical-trial-influenza-antiviral-avigan-favipiravir-covid-19-18505.html